|会社名||Huttig Building Products Inc. （ハッティグ・ビルディング・プロダクツ）|
|分野（sector）||Consumer Services 消費者サービス|
|産業（industry）||RETAIL: Building Materials|
|概要||事業概要 ヒュッティヒ・ビルディング・プロダクツ(Huttig Building Products Inc.)は主に住宅建設、住宅改善、改装および修繕作業に使用される木工品、建材および木製品の国内販売代理店である。同社は製品を製造業者から購入し、41以上の州にサービスを提供する約26の卸売物流センターを通じて販売する。同社の流通センターは、主として建築資材の販売業者、国内の購買グループ、ホームセンター、および製造された家屋の製造業者を含む工業ユーザーに製品を販売する。同社の製品は3つのカテゴリに分ける。木工品はドア、窓、モールディング、階段部品および柱を含む。一般建材はコンポジットデッキ、コネクター、ファスナー、ハウスラップ、ルーフィング製品および断熱材を含む。木製品は、床システムなどの加工木材製品、及び木製パネルと木材を含む。 ハッティグ・ビルディング・プロダクツは米国の住宅建築用資材販売会社。住宅の建設や改築、修理用に木工製品、建築資材、木材の販売を行う。木工製品、ドア、窓、モ―ルディング、階段パ―ツ、屋根製品、留め具、防水シ―ト、断熱・防音材、床システム、木製パネル、木材製品などを扱い、おもに資材販売業者、バイイング・グル―プ、ホ―ムセンタ―などに提供する。 Huttig, currently in its 136th year of business, is one of the largest domestic distributors of millwork, building materials and wood products used principally in new residential construction and in-home improvement, remodeling and repair work. Huttig distributes its products through 25 distribution centers serving 41 states. Huttig's wholesale distribution centers sell principally to building materials dealers, national buying groups, home centers and industrial users, including makers of manufactured homes.|
|本社所在地||555 Maryville University Drive Suite 400 St. Louis MO 63141 USA|
|代表者氏名||Delbert H. Tanner Delbert H. Tanner|
|代表者役職名||Chairman of the Board 取締役会会長|
|市場名||NASDAQ Small Cap|
|決算概要||決算概要 BRIEF: For the six months ended 30 June 2018 Huttig Building Products Inc revenues increased 13% to $421.4M. Net loss before extraordinary items totaled $300K vs. income of $1.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Operating Expenses increase of 9% to $82.2M (expense) Interest expense net increase from $1.3M to $2.8M (expense).|
Huttig Building Products, Inc. Announces Third Quarter 2021 Results 2021/11/03 20:00:00 Intrado Digital Media
Third Quarter 2021 Highlights (as compared to prior year quarter):
Huttig Building Products, Inc. Schedules Third Quarter 2021 Earnings Call 2021/10/20 14:30:00 Intrado Digital Media
ST. LOUIS, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Huttig Building Products (Nasdaq: HBP), one of the nation''s largest wholesale distributors of millwork and specialty building products used principally in new residential construction and home improvement, plans to release its third quarter 2021 financial results on Wednesday, November 3, 2021 after market close. An earnings call with management is scheduled for Thursday, November 4, 2021 at 10:00 a.m. Central Daylight Time.
Thursday Sector Leaders: Construction Materials & Machinery, Trucking Stocks 2021/10/14 16:47:27 iShook Finance
In trading on Thursday, construction materials & machinery shares were relative leaders, up on the day by about 2%. Leading the group were shares of Huttig Building Products, up about 21.1% and shares of Floor & Decor Holdings up about 3.5% on the day.
Huttig Building Products, Inc. Announces Review of Strategic Alternatives 2021/10/13 20:00:00 Intrado Digital Media
ST. LOUIS, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Huttig Building Products, Inc. (“Huttig” or the “Company”) (NASDAQ: HBP), a leading domestic distributor of millwork, building materials and wood products, today announced that its Board of Directors, consistent with its strategic review process and in consultation with its financial and legal advisors, has initiated a process to evaluate potential strategic alternatives to maximize shareholder value.
Proactive news headlines including AEX Gold, Helix BioPharma, Imagine AR, Empower Clinics and Kintara Therapeutics 2021/07/01 18:08:00 Intrado Digital Media
New York , July 01, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in the US and Canada, has covered the following companies:
Helix BioPharma spends C$1.9M on R&D in its fiscal third quarter 2021/06/15 12:19:00 Proactive Investors Canada
Helix BioPharma Corp (TSE:HBP) (OTCMKTS:HBPCF) (FRA:HBP) told investors that it spent around C$1.9 million on research and development (R&D) costs in its fiscal third quarter to April 30, 2021 as the biopharma continues to develop drugs to treat cancer using immuno-oncology. The company has developed an immune-oncology drug platform (DOS47) to treat cancer, which is designed to turn the tumor''s environment to alkaline from acid, which, in turn, corrects an impaired immune system. READ: Helix BioPharma closes first tranche of previously announced private placement with Lind Global Macro Fund for gross proceeds of C$3.5M R&D costs for the three months to April 30 were C$1.933 million, up from C$1.523 million in the same period a year earlier, the company said, as it reported three and nine-month figures. In terms of clinical development, the company said that for the LDOS001 study (a US Phase I L-DOS47 in combination with pemetrexed and carboplatin for lung cancer), it aims for a final clinical study report to be completed in September 2021.
Helix Biopharma: Fiscal Q3 Earnings Snapshot 2021/06/14 18:32:00 Brampton News
Helix Biopharma: Fiscal Q3 Earnings Snapshot Read the Full Post from The Brampton Guardian
31 Stocks Moving in Wednesday's Pre-Market Session 2021/03/10 12:19:45 Benzinga
Gainers MediciNova, Inc. (NASDAQ: MNOV ) shares rose 79.6% to $10.20 in pre-market trading after the biopharmaceutical company announced a partnership with the Biomedical Advanced Research and Development Authority (BARDA) to repurpose MN-166 (ibudilast) as a potential medical countermeasure against lung damage induced by chlorine gas. Exela Technologies, Inc. (NASDAQ: XELA ) rose 72.9% to $7.97 in pre-market trading. Exela Technologies shares jumped 179% on Tuesday after the company said it won a 10-year, $90-million contract delivering data transformation solutions for a major US insurer. Obalon Therapeutics, Inc. (NASDAQ: OBLN ) rose 50% to $5.31 in pre-market trading after climbing 18% on Tuesday. Atossa Therapeutics, Inc. (NASDAQ: ATOS ) shares rose 40.3% to $3.48 in pre-market trading after gaining over 16% on Tuesday. Atossa Therapeutics, last month, announced final results from its Phase 1 study evaluating AT-301 administered by nasal spray. AT-301 is being developed for at-home use for patients recently diagnosed with COVID-19..
Huttig Building Products Earnings and Growth Analysis : Stock market Insights & financial analysis 2020/10/29 20:22:00 Stock Market Daily
Huttig Building Products announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
Why Huttig Building Products Is Trading Higher Today 2020/10/15 18:50:21 Benzinga
Huttig Building Products (NASDAQ: HBP ) shares are trading higher on Thursday after Mill Road raised its acquisition offer for the company to $4 per share. Huttig Building Products is … Full story available on Benzinga.com
Huttig Building Products, Inc. (HBP) CEO Jon Vrabely on Q1 2019 Results - Earnings Call Transcript 2019/05/04 06:28:06 Seeking Alpha
Huttig Building Products, Inc. (NASDAQ:HBP) Q1 2019 Earnings Conference Call April 30, 2019 11:00 AM ET Company Participants Jon Vrabely - President, Chief Exec
関連キーワード （林産品_木材製品 米国株 ハッティグ・ビルディング・プロダクツ HBP Huttig Building Products Inc.）